A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-Blind, Vehicle-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily for 6 Months in Adolescents and Adult Subjects With Stable Patchy Alopecia Areata With Optional Long-Term Open-Label Extension
In the register
The register attaches this trial to ATI-50002 (Aclaris Therapeutics), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Terminated early
- Declared phase
- Phase 2
- Sponsor
- Aclaris Therapeutics, Inc.
- Participants (registry)
- 129
- Start
- November 2017
- Primary completion
- April 2019
- Study completion
- September 2019
- Last registry update
- June 2020
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: ATI-50002 high dose, ATI-50002 low dose, Placebo
Other trials of ATI-50002
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.